There are 2137 resources available
922P - EACH: A phase II study evaluating the safety and anti-tumour activity of avelumab and cetuximab in recurrent/metastatic squamous cell carcinomas
Presenter: Martin Forster
Session: E-Poster Display
Resources:
Abstract
923P - Immune alterations in a window of opportunity for durvalumab (MEDI4736) plus metformin trial in squamous cell carcinoma of the head and neck (SCCHN)
Presenter: Joseph Curry
Session: E-Poster Display
Resources:
Abstract
924P - SNS-301 added to pembrolizumab in patients (Pts) with ASPH+ advanced squamous cell carcinoma of the head & neck (SCCHN)
Presenter: Alain Algazi
Session: E-Poster Display
Resources:
Abstract
925P - Efficacy of 2nd line treatment with chemotherapy (CT) or immune checkpoint inhibitors (ICIs) for patients (pts) with a prolonged objective response (>6 months) after 1st line therapy for recurrent or metastatic head & neck squamous cell carcinoma (R/M-HNSCC)
Presenter: Agathe Vienne
Session: E-Poster Display
Resources:
Abstract
926P - Real-world data in the era of immune checkpoint inhibitors (ICIs): Cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
Presenter: Cheng Fu-ming
Session: E-Poster Display
Resources:
Abstract
927P - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as 2<sup>nd</sup> line treatment for PD-L1 unselected metastatic head and neck cancer patients
Presenter: Martin Forster
Session: E-Poster Display
Resources:
Abstract
928P - Phase I dose-expansion (part II) study of ISU104 (a novel anti-ErbB3 monoclonal antibody) alone and combination with cetuximab (CET), in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Presenter: Sung-Bae Kim
Session: E-Poster Display
Resources:
Abstract
929P - Anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: An interim analysis of a phase II clinical trial
Presenter: Qingqing Cai
Session: E-Poster Display
Resources:
Abstract
930P - Weekly paclitaxel, carboplatin and cetuximab (PCC) as first-line treatment of recurrent and/or metastatic head & neck squamous cell carcinoma (R/M-HNSCC) for patients ineligible to cisplatin based chemotherapy
Presenter: Helene Carinato
Session: E-Poster Display
Resources:
Abstract
931P - Topical steroid versus placebo for the prevention of radiation dermatitis in head and neck cancer patients receiving chemoradiotherapy: A phase III, randomized, double-blinded trial: J-SUPPORT 1602(TOPICS)
Presenter: Tomoya Yokota
Session: E-Poster Display
Resources:
Abstract